PinkDX to Develop Diagnostics that Address Women’s Unmet Medical Needs
PinkDx, an early-stage company focused on positively impacting the health of women, launched with $40 million in Series A financing.
PinkDx, an early-stage company focused on positively impacting the health of women, launched with $40 million in Series A financing.
This collaborative study seeks to represent a significant step forward in digital pathology and oncology breast cancer research
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.
The blood test is intended for screening colorectal cancer in people who are of average risk and not experiencing symptoms.
Read MoreThe Florida Health Department will use DiaCarta’s RadTox test for early detection of cancer treatment response and resistance.
Read MoreThe ASCCP recognized dual-stain biomarkers as an important tech to determine if an HPV infection is transforming into cervical pre-cancer.
Read MoreResearchers developed a deep-learning model to improve the 3D segmentation of glandular tissue structures for prostate cancer assessment.
Read MoreA new algorithm may help identify high-risk precancerous lesions on the fallopian tubes thought to lead to a common form of ovarian cancer
Read MoreThe Oncuria Bladder Cancer Tests, a DiaCarta validated lab developed test (LDT), received Medicare coverage effective Jan. 1, 2024.
Read MoreAI has helped scientists reveal a new form of aggressive prostate cancer which could revolutionize how the disease is diagnosed in the future.
Read MoreNaveris Launched an initiative aimed to expand the applications of its circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test.
Read MoreResearchers applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism.
Read MoreThe Riskguard test detects genetic changes that can increase risk for 10 common cancers, using a simple blood or saliva sample.
Read MoreResearchers developed a platform for integrating DNA and RNA data from single-cell sequencing with improved speed and precision.
Read MoreFor patients with metastatic HR+ breast cancer, there may be no test more important than monitoring for an ESR1 mutation.
Read MoreThe team will work to improve the genetic testing and clinical management of hereditary and multiple primary cancers in African Americans.
Read MoreBD partnered with Camtech Health to advance cervical cancer screening by offering women in Singapore the option to self-collect a sample.
Read MoreThe newly launched Cancer Screening Research Network (CSRN) will evaluate promising and emerging cancer screening technologies.
Read More